Dual GIP/GLP-1 Receptor Agonist
Tirzepatide
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. It represents a new class of peptide therapeutics with dual incretin action. Synthesized to ≥99% purity for research applications.
- Molecular Weight: 4,813.45 g/mol
- Sequence: 39 amino acid linear peptide
- Purity: ≥99% (HPLC verified)
- Storage: -20°C, lyophilized
Total
$349.00
+ $25.00 Flat Rate Shipping
For research use only. By purchasing, you agree to our terms of service.
Common Schedule
Tirzepatide Titration Timeline
Gradually increasing your dose helps minimize side effects and allows your body to adjust. Consult your healthcare provider for personalized guidance.
Weeks 1–4
2.5 mg
Starting dose
Weeks 5–8
5.0 mg
Per week dose
Weeks 9–12
7.5 mg
Per week dose
Weeks 13–16
10.0 mg
Per week dose
Weeks 17–20
12.5 mg
Per week dose
Week 21+
15.0 mg
Maintenance
Weeks 1–4Starting dose
2.5 mg
Weeks 5–8Per week dose
5.0 mg
Weeks 9–12Per week dose
7.5 mg
Weeks 13–16Per week dose
10.0 mg
Weeks 17–20Per week dose
12.5 mg
Week 21+Maintenance
15.0 mg